BeiGene, Ltd.'s latest marketcap:

About BeiGene, Ltd.

BeiGene, Ltd. is an oncology-focused company dedicated to discovering and developing innovative treatments for cancer patients worldwide. Operating in the United States, China, Europe, and other international markets, the company is committed to advancing cancer care through cutting-edge therapies.

Commercial Stage Products

• BRUKINSA: A small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for treating various blood cancers.
• TEVIMBRA: An anti-PD-1 antibody immunotherapy targeting solid tumors and blood cancers.
• PARTRUVIX: A selective small molecule inhibitor of PARP1 and PARP2 enzymes, under evaluation for solid tumors.

Clinical Stage Products

BeiGene’s pipeline includes a diverse range of investigational therapies:

• Sonrotoclax (BGB-11417) – Bcl-2 inhibitor
• BGB-16673 – BTK-targeting chimeric degradation activation compound
• Ociperlimab (BGB-A1217) – TIGIT inhibitor
• BG-60366 – EGFR-targeted CDAC
• BG-89894 (SYH2039) – MAT2A Inhibitor
• BGB-58067 – MTA-Cooperative PRMT5 Inhibitor
• BG-T187 – Anti-EGFRxMET trispecific antibody
• BGB-26808 – HPK-1 Inhibitor
• BGB-C354 – Anti-B7H3 ADC
• Zanidatamab – Bispecific HER2-targeted antibody
• BG-C137 – Anti-FGFR2b ADC
• BGB-53038 – Pan-KRAS Inhibitor
• BGB-B2033 – Anti-GPC3x4-1BB bispecific antibody
• BGB-B3227 – Anti-MUC1xCD16A bispecific antibody
• BG-C477 – Anti-CEAADC
• BGB-43395 – CDK4 Inhibitor
• BG-68501 – CDK2 Inhibitor
• BG-C9074 – Anti-B7H4 ADC
• BGB-21447 – Bcl-2 Inhibitor
• BGB-45035 – IRAK4-targeted CDAC

Collaborations & Partnerships

BeiGene has strategic agreements with leading pharmaceutical companies, including:

• Amgen
• BMS
• Bio-Thera
• EUSA Pharma
• Luye Pharmaceutical
• Novartis

Company Background

Founded in 2010, BeiGene, Ltd. is headquartered in Camana Bay, the Cayman Islands. The company continues to expand its research and development efforts to address unmet medical needs in oncology.